MX2017012694A - Metodos para tratar la obesidad y la enfermedad del higado graso no alcoholica o esteatohepatitis no alcoholica utilizando anticuerpos antagonistas del receptor de glucagon. - Google Patents

Metodos para tratar la obesidad y la enfermedad del higado graso no alcoholica o esteatohepatitis no alcoholica utilizando anticuerpos antagonistas del receptor de glucagon.

Info

Publication number
MX2017012694A
MX2017012694A MX2017012694A MX2017012694A MX2017012694A MX 2017012694 A MX2017012694 A MX 2017012694A MX 2017012694 A MX2017012694 A MX 2017012694A MX 2017012694 A MX2017012694 A MX 2017012694A MX 2017012694 A MX2017012694 A MX 2017012694A
Authority
MX
Mexico
Prior art keywords
methods
glucagon receptor
nonalcoholic
fatty liver
liver disease
Prior art date
Application number
MX2017012694A
Other languages
English (en)
Other versions
MX392496B (es
Inventor
Yan Hai
SHI Jim
Oh Jeong
Original Assignee
Remb Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remb Biotherapeutics Inc filed Critical Remb Biotherapeutics Inc
Publication of MX2017012694A publication Critical patent/MX2017012694A/es
Publication of MX392496B publication Critical patent/MX392496B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere a métodos para tratar o prevenir la obesidad y/o las enfermedades de hígado graso no alcohólicas (NAFLDs) y/o esteatohepatitis no alcohólica (NASH) utilizando un agente bloqueador del receptor de glucagón. En diversas modalidades, la presente descripción se refiere a métodos para tratar o prevenir NAFLD/NASH utilizando proteínas de unión a antígenos y antagonistas, e.g., anticuerpos totalmente humanos, que se unen específicamente y antagonizan la función del receptor de glucagón humano.
MX2017012694A 2015-04-02 2016-03-31 Anticuerpos antagonistas del receptor de glucagón para usarse en el tratamiento de la obesidad y la enfermedad del hígado graso no alcohólica o esteatohepatitis no alcohólica. MX392496B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562142257P 2015-04-02 2015-04-02
PCT/US2016/025336 WO2016161154A1 (en) 2015-04-02 2016-03-31 Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodies

Publications (2)

Publication Number Publication Date
MX2017012694A true MX2017012694A (es) 2018-03-07
MX392496B MX392496B (es) 2025-03-24

Family

ID=57006366

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012694A MX392496B (es) 2015-04-02 2016-03-31 Anticuerpos antagonistas del receptor de glucagón para usarse en el tratamiento de la obesidad y la enfermedad del hígado graso no alcohólica o esteatohepatitis no alcohólica.

Country Status (9)

Country Link
US (2) US10752693B2 (es)
EP (1) EP3277830A4 (es)
JP (1) JP6861641B2 (es)
KR (1) KR20170138456A (es)
CN (1) CN107614695B (es)
AU (1) AU2016242935B2 (es)
CA (1) CA2980765A1 (es)
MX (1) MX392496B (es)
WO (1) WO2016161154A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10226474B2 (en) 2017-01-09 2019-03-12 Temple University—Of The Commonwealth Sytem Of Higher Education Methods and compositions for treatment of non-alcoholic steatohepatitis
BR112019015479A2 (pt) 2017-01-27 2020-03-31 Ngm Biopharmaceuticals, Inc. Anticorpo e seu uso, célula, composição, molécula polinucleotídica, vetor, método para inibir a sinalização de gcgr, método para reduzir ou baixar os níveis de glicose, método para aumentar o nível de peptídeo c, método para aumentar o nível de insulina, método para tratar diabetes, método para tratar hiperglicemia, método para tratar uma doença, método para melhorar a função das células
CA3072118A1 (en) * 2017-08-09 2019-02-14 Sanofi Glp-1/glucagon receptor agonists in the treatment of fatty liver disease and steatohepatitis
WO2019173417A1 (en) * 2018-03-08 2019-09-12 Phanes Therapeutics, Inc. Anti-tip-1 antibodies and uses thereof
CN110357959B (zh) 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
US10961315B2 (en) 2018-07-27 2021-03-30 Ngm Biopharmaceuticals, Inc. Method of treating type I diabetes by administering a combination of a glucagon receptor antagonist and an anti-CD3 antibody
CN111068042B (zh) * 2018-10-18 2023-10-13 中山大学 一种多肽化合物在制备治疗非酒精性肝病、特发性肺间质纤维化和动脉硬化药物中的应用
US12251364B2 (en) * 2018-11-06 2025-03-18 Georgetown University Treating non-alcoholic steatohepatitis with cck inhibitors
CA3123979A1 (en) 2018-12-21 2020-06-25 Jiangsu Hengrui Medicine Co., Ltd. Bispecific protein
WO2025178928A1 (en) * 2024-02-23 2025-08-28 Remd Biotherapeutics, Inc. Combination therapy for the treatment of obesity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
US8501686B2 (en) 2008-06-05 2013-08-06 University Of Michigan Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects
EP2300037B1 (en) * 2008-06-17 2016-03-30 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
EP2758533B1 (en) * 2011-09-20 2018-04-11 Ionis Pharmaceuticals, Inc. Antisense modulation of gcgr expression
WO2014181229A2 (en) * 2013-05-07 2014-11-13 Rinat Neuroscience Corp. Anti-glucagon receptor antibodies and methods of use thereof
EP3151855B1 (en) * 2014-06-08 2021-11-24 REMD Biotherapeutics, Inc. Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies

Also Published As

Publication number Publication date
EP3277830A4 (en) 2018-11-21
CN107614695A (zh) 2018-01-19
EP3277830A1 (en) 2018-02-07
US20180079820A1 (en) 2018-03-22
AU2016242935B2 (en) 2020-10-01
CN107614695B (zh) 2022-01-25
AU2016242935A1 (en) 2017-11-09
JP6861641B2 (ja) 2021-04-21
US20200339697A1 (en) 2020-10-29
MX392496B (es) 2025-03-24
WO2016161154A1 (en) 2016-10-06
CA2980765A1 (en) 2016-10-06
US10752693B2 (en) 2020-08-25
JP2018512417A (ja) 2018-05-17
KR20170138456A (ko) 2017-12-15

Similar Documents

Publication Publication Date Title
MX392496B (es) Anticuerpos antagonistas del receptor de glucagón para usarse en el tratamiento de la obesidad y la enfermedad del hígado graso no alcohólica o esteatohepatitis no alcohólica.
CY1122840T1 (el) Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3
CY1122804T1 (el) Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα)
CU24498B1 (es) Anticuerpos de factor xi
PL3176181T3 (pl) Przeciwciało monoklonalne anty-CTLA4 lub jego fragment wiążący antygen, kompozycja lecznicza i zastosowanie
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
JO3686B1 (ar) جلوكان ومركبات مساعِدات glp-1 مشتركة
PE20180499A1 (es) Anticuerpos de union a tau
DOP2016000133A (es) Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este
PE20161210A1 (es) Anticuerpos anti-mcam y metodos de uso asociados
MX2022015250A (es) Un anticuerpo anti-il-23a para usarse en el tratamiento de la enfermedad de crohn.
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
MX2015016978A (es) Proteinas de union a antigeno neutralizantes de citomegalovirus.
BR112017002173A2 (pt) anticorpos semelhantes à angiopoietina e métodos de uso
CL2018000357A1 (es) Polipéptidos mrka, anticuerpos y usos los mismos
BR112018015090A2 (pt) anticorpo anti-trombina, fragmento de ligação ao antígeno e uso farmacêutico dos mesmos
UY37598A (es) Anticuerpos miméticos de fgf21 y usos de los mismos
AR101671A1 (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
MX2018007925A (es) Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo.
WO2014143739A3 (en) Anti-alpha v beta 6 antibodies and uses thereof
MX2017011480A (es) Anticuerpo de anti-esclerostina, fragmento de union a antigeno y uso medico del mismo.
MA40536A (fr) Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations
MX2018005097A (es) Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5.
BR112018016383A2 (pt) método para tratar uma doença autoimune, e, anticorpo ou fragmento de ligação específico do mesmo
BR112018070919A2 (pt) anticorpos anti-tim-3 e composições